Peyronie's Disease Treatment in India
Get Peyronie's Disease Treatment at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Peyronie's Disease Treatment in UAE
Peyronie's Disease Treatment at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Peyronie's Disease Treatment encompasses a spectrum of evidence-based interventions—from pharmacological collagenase injections (Xiaflex/CCH) and intralesional verapamil to surgical plaque excision with grafting and penile prosthesis implantation—achieving clinically meaningful curvature correction and functional restoration in 70–90% of appropriately selected patients. GAF Healthcare connects international patients with JCI- and NABH-accredited hospitals in India and JCI- and DHA-licensed centres in Dubai and Abu Dhabi, where fellowship-trained andrologists and urologists deliver these complex procedures at a fraction of Western costs. Patients benefit from zero waiting lists, end-to-end concierge coordination, and internationally benchmarked outcomes that make India and the UAE the leading destinations for affordable, high-quality Peyronie's Disease care.
Hospital Stay: 1–3 days (non-surgical/injection therapy: outpatient; surgical correction: 1–3 days inpatient) • Total Stay in Country (Fit-to-Fly): 1–3 weeks (injection series: 1 week post-final cycle; surgical cases: 2–3 weeks post-operatively, surgeon-cleared) • Success Rate: 70–90% (curvature correction ≥20°; prosthetic implantation satisfaction >90%)
What Is It?
Peyronie's Disease (PD) is a fibrotic disorder of the tunica albuginea—the dense fibro-elastic sheath encasing the erectile bodies—characterised by the formation of inelastic collagen plaques (predominantly Type III collagen replacing Type I) that disrupt penile biomechanics. The plaques create a tethering effect during erection, producing penile curvature (typically dorsal, ranging 30°–90°+), hourglass deformity, hinge defect, or shortening, and in moderate-to-severe cases cause penetration-impairing deformity, coital pain, and erectile dysfunction (ED) in up to 79% of affected men. The condition has an estimated prevalence of 3–9% in adult males, though real-world figures are likely higher due to under-reporting, and it is increasingly recognised in men aged 30–70, frequently following blunt or repetitive micro-trauma during intercourse.
Physiologically, the fibrotic cascade is driven by TGF-β1-mediated myofibroblast activation and reactive oxygen species, leading to progressive plaque calcification over a 12–18 month 'active phase', after which the disease typically stabilises into the 'chronic/stable phase'. The active phase is characterised by painful erections and changing curvature; the chronic phase features a fixed deformity and resolution of pain. This biological staging directly determines treatment eligibility: intralesional and mechanical therapies are most effective during active or early chronic phases, while surgical reconstruction is reserved for men in the stable chronic phase with a deformity that precludes satisfactory intercourse.
The standard of care, as defined by the American Urological Association (AUA) and European Association of Urology (EAU) guidelines, stratifies treatment by disease phase, deformity severity (measured by dynamic duplex ultrasound or a validated penile photograph with a goniometer), erectile function (assessed by IIEF-5 scoring), and patient goals. Collagenase Clostridium histolyticum (CCH/Xiaflex) remains the only FDA-approved intralesional pharmacotherapy, recommended for men with stable disease, palpable plaque, and curvature ≥30°. Surgical options—Nesbit/modified plication for mild-to-moderate curvature with adequate penile length, and plaque incision/excision with grafting (pericardium, SIS, or TachoSil) for severe or complex deformity—are the definitive correction standards. Men with concurrent refractory ED are best served by inflatable penile prosthesis (IPP) implantation with intraoperative modelling.
Candidates
• IDEAL SURGICAL CANDIDATES (Plaque Incision/Excision with Grafting or Plication):
- Stable Peyronie's Disease: curvature unchanged for ≥3 months (AUA definition of stability)
- Curvature ≥30° causing penetration difficulty or complete inability to have intercourse
- Adequate baseline erectile function (IIEF-5 ≥17) or ED responsive to PDE5 inhibitors (for plication/grafting procedures)
- Penile length sufficient to tolerate plication (typically >11 cm stretched penile length; shorter cases directed toward grafting)
- Hourglass, hinge, or multiplanar deformity not correctable by plication alone
• IDEAL CANDIDATES FOR COLLAGENASE CCH (XIAFLEX) INJECTION SERIES:
- Active or early stable phase PD with curvature 30°–90°
- Palpable, non-calcified plaque on physical examination confirmed by high-frequency (7.5–15 MHz) penile ultrasound
- Absence of septal scar or calcium deposits (calcified plaques respond poorly to enzymatic therapy)
- Patient willing to perform penile modelling/stretching exercises and use vacuum erection device (VED) between cycles
• CANDIDATES FOR INFLATABLE PENILE PROSTHESIS (IPP) WITH MODELLING:
- Peyronie's Disease with concurrent severe or refractory ED non-responsive to pharmacotherapy
- Men who prioritise both curvature correction and reliable erection restoration in a single procedure
- Stable disease phase mandatory before prosthetic implantation
• REQUIRED DIAGNOSTIC WORK-UP:
- Penile Dynamic Duplex Ultrasound (PDDU): peak systolic velocity (PSV), end-diastolic velocity (EDV), and resistive index to characterise plaque location, calcification, and vascular status (venous leak assessment)
- Standardised Erect Penile Photography: goniometric curvature measurement in each plane; PDDU-assisted pharmacological erection (intracavernosal alprostadil 10–20 mcg) for objective deformity mapping
- IIEF-5 (International Index of Erectile Function) questionnaire: baseline erectile function scoring
- PDQ (Peyronie's Disease Questionnaire): validated bother score for symptom severity and psychosocial impact
- Serum testosterone, fasting glucose, HbA1c, lipid panel: metabolic co-morbidity assessment
- Serum PSA (if age >45): pre-surgical baseline
- Full Blood Count, Coagulation Profile (PT/INR/aPTT), Renal and Liver Function Tests: pre-operative fitness
• CONTRAINDICATIONS:
- Active phase PD with evolving curvature: surgery is contraindicated until disease is stable
- Calcified plaque: relative contraindication to CCH injection; ultrasound or plain X-ray must confirm absence of calcification before enzymatic therapy
- Active penile or systemic infection: absolute contraindication to any invasive procedure
- Severe coagulopathy or anticoagulation not bridgeable perioperatively
- Unrealistic patient expectations regarding penile length restoration (counselling mandatory pre-operatively)
- Concurrent active malignancy under treatment
Procedure
PHARMACOLOGICAL / MINIMALLY INVASIVE THERAPIES
1. Intralesional Collagenase Clostridium histolyticum (CCH / Xiaflex) The only FDA/EMA-approved pharmacotherapy. A standard treatment cycle consists of 2 injections administered 24–72 hours apart into the plaque, followed by penile modelling under physician guidance, repeated up to 4 cycles (8 injections total) at 6-week intervals. CCH selectively cleaves Type I and III collagen fibres within the plaque. The IMPRESS I & II pivotal trials demonstrated a mean curvature improvement of ~34% (vs. ~18% placebo) and significant PDQ bother score reduction. GAF partner centres use high-resolution ultrasound guidance for injection precision, reducing the risk of corporal injury. Penile traction therapy (PTT) with a validated device (FastSize, RestoreX) is initiated between injection cycles to augment length recovery and modelling effect.
2. Intralesional Verapamil (ILV) Calcium-channel blocker injected directly into the plaque (10 mg/10 mL in saline; biweekly for 6 months). Mechanistically inhibits fibroblast proliferation and stimulates collagenase activity, reducing plaque volume. Used primarily in active-phase disease or as an adjunct when CCH is unavailable or contraindicated. Response rates for curvature improvement are modest (~25–30%) but the safety profile is favourable.
3. Intralesional Interferon-α2b Biological agent that downregulates TGF-β1 and reduces fibroblast proliferation. Administered biweekly for 12 weeks; supported by RCT data showing curvature improvement and pain reduction. Considered when CCH is not accessible.
4. Extracorporeal Shockwave Therapy (ESWT) Low-intensity focused shockwaves applied transcutaneously to the plaque (typically 2,000–3,000 pulses at 0.09–0.25 mJ/mm², 3 sessions/week for 3–6 weeks). Primarily effective for pain relief in the active phase; evidence for curvature correction is limited and the AUA does not recommend it as a curvature-correcting monotherapy but it is widely used for pain management.
5. Penile Traction Therapy (PTT) & Vacuum Erection Device (VED) Standalone or adjunctive mechanical therapies applying controlled tensile force to remodel scar tissue. Validated devices (RestoreX) used ≥30 minutes/day over 3–6 months show curvature reductions of 15–25° and length gains of 0.5–1.5 cm in clinical studies. Used perioperatively to protect penile length.
SURGICAL THERAPIES (Stable/Chronic Phase)
6. Penile Plication (Nesbit Procedure & Modified Variants: 16-dot, Yachia) The gold standard for men with mild-to-moderate curvature (≤60°), no significant hourglass/hinge deformity, and adequate penile length. The convex (opposite) side of the tunica albuginea is plicated using permanent (Prolene 2-0) or absorbable sutures to counteract the curvature produced by the inelastic plaque. The procedure avoids plaque manipulation, carries minimal erectile function risk, and has a high patient satisfaction rate (~80–85%). It does result in a degree of penile shortening (typically 0.5–2 cm), which must be counselled pre-operatively using the Kelâmi nomogram.
7. Plaque Incision / Excision with Grafting (Lue Technique, H-incision) Indicated for severe curvature (>60°), significant shortening, or complex multiplanar or hourglass/hinge deformity where plication would sacrifice excessive length. The plaque is incised (H-shape, fish-mouth) or partially excised, creating a defect that is covered with a graft. Graft materials in current use include: - Pericardial allograft (bovine or equine): widely used, excellent handling properties - Small Intestinal Submucosa (SIS/Surgisis): acellular biocompatible matrix - Tunica vaginalis autograft: patient's own tissue, no rejection risk - TachoSil (fibrin sealant patch): emerging evidence in small series Grafting carries a higher risk of de novo ED (5–25% depending on baseline vascular status) due to dissection near neurovascular bundles; intraoperative pharmacological erection testing with duplex assessment is performed to verify deformity correction and graft integrity. Penile Doppler imaging pre-operatively stratifies vascular risk.
8. Inflatable Penile Prosthesis (IPP) Implantation with Manual Modelling The procedure of choice for men with PD and concurrent severe/refractory ED. A 3-piece IPP (AMS 700 CX, Coloplast Titan, or equivalent) is implanted via a subcoronal or infrapubic approach. Following cylinder placement, the device is fully inflated and the penis is manually modelled (Mulcahy technique) to fracture or stretch the plaque and achieve straightening. Residual curvature >30° post-modelling can be addressed by adjunctive incision/grafting over the prosthesis or plication. Curvature correction rates exceed 85%; patient satisfaction rates for IPP in this indication exceed 90% in long-term series. GAF partner centres perform this procedure laparoscopically-assisted in select cases for improved visualisation.
Cost of Peyronie's Disease Treatment: India vs. UAE
The cost of Peyronie's Disease Treatment varies significantly depending on the chosen intervention—from a single outpatient injection cycle to complex surgical reconstruction with grafting or prosthesis implantation—as well as the destination country. India offers world-class andrology expertise at 40–60% lower cost than the UAE, making it the preferred destination for cost-conscious patients. The UAE (Dubai and Abu Dhabi) provides premium hospital environments, seamless Western-standard luxury care, and exceptional flight connectivity, appealing to patients from the Middle East, Africa, and Europe. Both destinations are represented by JCI-accredited institutions through GAF Healthcare, ensuring equivalent clinical safety and outcomes regardless of budget.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $1,500 – $6,500 | ~54% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $3,500 – $14,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PRE-OPERATIVE / PRE-TREATMENT PHASE (Days 1–7 after arrival)
Day 1–2: Arrival & Consultation
• Airport transfer by GAF Healthcare coordinator; hotel or hospital guest house check-in
• Comprehensive andrology/urology consultation with review of all prior imaging and records sent in advance
• Baseline penile dynamic duplex ultrasound (PDDU) with pharmacological erection (intracavernosal alprostadil)
• Standardised erect penile photography with goniometric curvature measurement
• IIEF-5 and PDQ questionnaire administration
• Blood work: CBC, coagulation, metabolic panel, testosterone, HbA1c, PSA
• Anaesthesia fitness assessment (ECG, chest X-ray if indicated)
Day 3–4: Multidisciplinary Review & Treatment Planning
• Andrologist, anaesthetist, and nurse coordinator team review all diagnostics
• Shared decision-making consultation: patient and family briefed on all options (injection series vs. surgery), risks, realistic outcomes, and penile length impact
• Consent obtained; surgical scheduling confirmed or injection programme started
• Cardiological or endocrinological clearance arranged same-day if metabolic co-morbidities identified
Day 5–7 (if surgical): Pre-operative Preparation
• NPO (nil per os) from midnight before surgery
• Bowel prep not required; antiseptic shower
• Pre-operative antibiotics (cefazolin 1g IV or allergy-adjusted alternative) administered 30–60 min pre-incision
• Thromboprophylaxis: TED stockings + LMWH (enoxaparin) initiated evening before or per anaesthesia protocol
INTRA-OPERATIVE PHASE (Day of Surgery: typically Day 5–7)
Surgical Duration:
• Plication procedures: 60–90 minutes under spinal or general anaesthesia
• Plaque excision with grafting: 2–3 hours under general anaesthesia
• IPP implantation with modelling: 2–3 hours under spinal or general anaesthesia
Key Intraoperative Steps (Grafting/Plication example):
1. Subcoronal circumferential incision with degloving of penile skin to expose tunica albuginea
2. Neurovascular bundle identification and protection (Buck's fascia dissection)
3. Artificial pharmacological erection induction (intracavernosal saline/alprostadil) to map deformity precisely
4. Plaque incision (H-configuration) or plication suture placement at maximum curvature point
5. Graft inset and fixation (for grafting cases); repeat artificial erection to confirm straightening
6. Watertight closure; skin re-approximation; compressive dressing and urinary catheter placement
IMMEDIATE POST-OPERATIVE PHASE (Day 1–3 post-surgery in hospital)
• Urinary catheter remains in situ 24–48 hours
• IV analgesia (paracetamol + NSAID ± opioid PRN); transition to oral analgesia Day 1
• Penile dressing change Day 1; wound inspection
• Thromboprophylaxis continued until mobile
• Discharge criteria: voiding independently, pain controlled on oral medications, no signs of haematoma or infection
• For IPP patients: pump cycling education with nurse before discharge
EARLY RECOVERY (Weeks 1–3 in-country)
Week 1:
• Wound care instructions; waterproof dressing; avoid submersion (no baths/pools)
• Oral antibiotics (typically ciprofloxacin or trimethoprim/sulfamethoxazole) for 5–7 days
• Penile oedema and bruising expected; ice pack intervals
• Strict sexual abstinence; no manual stimulation
• PDE5 inhibitor initiated at low dose (sildenafil 25–50 mg nightly) from Day 14 post-grafting to promote oxygenated blood flow and protect erectile function (penile rehabilitation protocol)
• Follow-up clinic review at Day 7: wound check, early deformity assessment
Week 2–3:
• Penile traction device (PTT) initiated at Week 3 post-surgery (plication/grafting cases) to mitigate scar contracture and preserve length
• IPP patients begin device cycling (inflation/deflation) at 4–6 weeks under instruction
• Surgeon-issued fit-to-fly certificate typically issued at 2–3 weeks for surgical cases (confirmed at follow-up visit before departure)
• GAF coordinator arranges discharge summary, imaging reports, operative notes, and pathology (if plaque excised) for handover to home country physician
MID-TO-LONG-TERM RECOVERY (Weeks 4–24 at home)
Week 4–6: Return of spontaneous erections; continued penile rehabilitation with PDE5i and PTT
Week 6–8: Sexual activity may resume (surgeon clearance required); gradual return to full activity
Week 12: Formal assessment of curvature correction; IIEF-5 and PDQ re-administered
Months 6–12: Final functional and cosmetic outcome assessment; residual curvature addressed if >15° and symptomatic (rarely required)
FOR INJECTION (CCH) PROGRAMME PATIENTS:
• Cycle 1: Injections Day 1 & Day 3; modelling session Day 3; discharge Day 4
• Return for Cycles 2–4 at 6-week intervals (GAF coordinates telemedicine monitoring between visits)
• Fit-to-fly: 5–7 days after each injection cycle
• Full programme completion: 6 months (4 cycles); final outcome assessment at Month 6
Risks & Considerations
Peyronie's Disease Treatment, while generally safe in experienced hands, carries a spectrum of procedure-specific risks that patients must understand before proceeding. For intralesional CCH (Xiaflex) injection therapy, the most serious risk is corporal rupture (penile fracture equivalent), reported in <1% of cases in the IMPRESS trials; it requires immediate surgical repair and is mitigated by strict adherence to injection technique and modelling protocols. Bruising, swelling, and injection-site pain are nearly universal after each cycle (>85%) and resolve within 2–4 weeks. Skin break or penile skin tears occur in ~5% and typically heal conservatively. For surgical plication procedures, the primary risk is penile shortening (0.5–2.0 cm), which is predictable and should be quantified pre-operatively using Kelâmi's formula; de novo ED is rare (<5%) as the plaque is not disturbed. For plaque incision/excision with grafting, the most clinically significant risk is de novo or worsened ED, occurring in 5–25% of cases depending on baseline vasculogenic status (PDDU-measured PSV <25 cm/s pre-operatively is a significant risk factor); partial sensory changes or glans hypoaesthesia from neurovascular bundle proximity can occur in 5–15% and are usually transient. Recurrent curvature is reported in 5–10% of cases at 5-year follow-up for all surgical approaches. For inflatable penile prosthesis (IPP) implantation, device infection is the most feared complication (1–3% in antibiotic-coated devices such as AMS 700 InhibiZone or Coloplast Titan OTR), requiring device explantation if it occurs; mechanical failure rates are <5% at 10 years with modern 3-piece devices. Residual curvature post-IPP modelling (>30°) requiring adjunctive intervention occurs in approximately 10–15% of cases. Across all interventions, patients should be counselled that Peyronie's Disease cannot be fully 'cured' in the sense of complete plaque elimination; the realistic goal is functional straightening sufficient for intercourse, with variable length and girth outcomes. Patients with significant psychosexual distress related to PD should receive concurrent psychological support, as depression and relationship impact are documented in >50% of affected men.
Top Hospitals for Peyronie's Disease Treatment
Top Doctors for Peyronie's Disease Treatment
Internationally trained specialists in Urology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Gaurav Kataria
MCh, MS, MBBS
Urologist
Paras Hospitals, Gurgaon, India
23+ Yearsof experience
Dr. Gaurav Kataria is a Senior Consultant Urologist at Paras Hospitals in Gurgaon with more than 23 years of clinical experience in urological care and genito-urinary surgery. He completed his MCh in Urology from the prestigious Jawaharlal Institute of Post Graduate Medical Education and Research (JIPMER) in 2017, building on a strong foundation of MS in General Surgery (2011) and MBBS (2005). His credentials reflect a commitment to advanced surgical… Read more
Dr. Gutta Srinivas
MBBS, MS, DNB
Urologist & Transplant Surgeon
Yashoda Hospitals, Hi-Tech City, Hyderabad, India
25+ Yearsof experience
Dr. Gutta Srinivas is a Senior Consultant Urologist and Transplant Surgeon serving as Clinical Director of the Department of Urology at Yashoda Hospitals, Hi-Tech City, Hyderabad. With over 25 years of clinical experience, he has established himself as a leading figure in urological surgery and renal transplantation across India. His pioneering work includes performing India's first ABO-incompatible kidney transplant using the Adsorbent Technique—a… Read more
Dr. Jangvir Singh Grewal
MBBS, MS in General Surgery, MCh in Urology and Renal Transplant Program, DrNB in Genitourinary Surgery
Urologist
Medanta - The Medicity, Gurugram, India
3+ Yearsof experience
Dr. Jangvir Singh Grewal is an Associate Consultant in Urology at Medanta - The Medicity, Gurugram, where he brings over three years of clinical experience in managing complex urological and renal conditions. He holds an MCh in Urology and Renal Transplant Program from Madurai Medical College (completed 2023), a DrNB in Genitourinary Surgery, and an MS in General Surgery from Pt. B.D. Sharma PGIMS, UHS Rohtak, providing him with a strong surgical… Read more
Dr. Lokesh Sinha
MBBS, MS, DNB
Urologist
Gleneagles Hospital, Mumbai, India
16+ Yearsof experience
Dr. Lokesh Sinha is a Senior Consultant Urologist at Gleneagles Hospital in Mumbai with over 16 years of clinical excellence in urological surgery. He holds a prestigious academic background with MBBS, MS, and DNB qualifications, and was awarded a Gold Medal in MS for General Surgery, reflecting his exceptional surgical skill and commitment to patient care. His surgical practice spans the full spectrum of modern urology, with particular expertise in… Read more
Dr. M. Gopichand
MBBS, MCh (Urology & Andrology), DNB (Urology)
Urologist
Yashoda Hospitals, Hyderabad, India
26+ Yearsof experience
Dr. M. Gopichand is a Senior Consultant Urologist at Yashoda Hospitals in Hyderabad with over 26 years of distinguished clinical practice in urology. He holds an MCh in Urology & Andrology from Bombay Hospital Institute of Medical Sciences and a DNB in Urology from New Delhi, credentials that underpin his comprehensive expertise across the full spectrum of urological diseases. He is recognized as one of South India's most accomplished urologists,… Read more
Frequently Asked Questions — Peyronie's Disease Treatment
The total cost of Peyronie's Disease Treatment depends primarily on the chosen intervention. In India, at JCI- and NABH-accredited partner hospitals, a single intralesional CCH (Xiaflex) injection cycle (outpatient) costs approximately USD 1,500–2,500; a full 4-cycle programme ranges USD 4,000–6,500 inclusive of repeat visits. Penile plication surgery (Nesbit/16-dot) costs USD 2,000–3,500 all-in (surgeon, anaesthesia, 1–2 day hospital stay, standard medications). Plaque incision/excision with grafting ranges USD 3,000–5,500, and inflatable penile prosthesis (IPP) implantation with modelling is USD 4,500–6,500 depending on device brand. In the UAE (Dubai/Abu Dhabi), at JCI-accredited and DHA/DoH-licensed centres, the equivalent costs are substantially higher reflecting premium infrastructure and operational costs: CCH injection cycle USD 3,500–5,000; full 4-cycle programme USD 10,000–14,000; plication surgery USD 4,500–7,000; grafting surgery USD 6,000–10,000; IPP implantation USD 8,000–14,000. India is typically 40–60% more affordable than the UAE for identical procedures performed by fellowship-trained andrologists. All GAF Healthcare packages are itemised transparently—there are no hidden facility or interpretation fees. Cost savings on treatment in India or the UAE versus the USA, UK, or Australia frequently exceed 60–75% even after accounting for international flights and accommodation.
The fit-to-fly timeline depends on the specific treatment received. For intralesional injection therapy (CCH/Xiaflex or verapamil): each injection cycle is an outpatient procedure; patients can typically fly home 5–7 days after the final injection of each cycle, once local swelling and bruising have resolved and there are no signs of skin tear or corporal injury. Since a full CCH programme involves 4 cycles at 6-week intervals, patients travelling for a single cycle can return home within one week of treatment. For penile plication surgery (Nesbit/16-dot technique): hospital stay is 1–2 days; most patients are cleared to fly 10–14 days post-operatively, once wound integrity is confirmed and they are comfortable in a seated aircraft position. For plaque incision/excision with grafting: hospital stay is 2–3 days; the fit-to-fly window is typically 2–3 weeks post-operatively due to the more extensive surgical dissection, the need for wound inspection, and confirmation of graft take. For inflatable penile prosthesis (IPP) implantation: hospital stay is 2–3 days; patients are generally cleared to fly 2–3 weeks post-operatively, after a wound check and initial device cycling instruction. A formal fit-to-fly certificate, required by most airlines for passengers within 4 weeks of major surgery, is issued by the treating GAF-affiliated surgeon before departure. Patients are advised to wear compression stockings on the flight and ambulate regularly to reduce DVT risk. Final guidance is always individualised based on the patient's healing progress at their pre-departure clinical review.
Success rates for Peyronie's Disease Treatment are intervention-specific and must be understood in the context of what 'success' means clinically—functional straightening sufficient for satisfactory intercourse, not complete elimination of the plaque. For collagenase CCH (Xiaflex) injection therapy: the IMPRESS I & II Phase III pivotal trials (the largest RCTs in PD pharmacotherapy) demonstrated a mean penile curvature improvement of approximately 34% (vs. 18% placebo), with ~40% of men achieving a clinically meaningful response (≥20° improvement); combined with penile traction therapy, real-world response rates approach 50–60%. For penile plication (Nesbit/16-dot): surgical straightening to <15° residual curvature is achieved in 85–95% of appropriately selected patients, with patient satisfaction rates of 80–85% at 2-year follow-up; the trade-off is predictable penile shortening of 0.5–2.0 cm. For plaque incision/excision with grafting: curvature correction rates of 85–95% are reported in high-volume centres; however, de novo erectile dysfunction occurs in 5–25% depending on pre-operative vascular status, and long-term recurrence of curvature affects 5–10% of patients at 5 years. For inflatable penile prosthesis (IPP) implantation with modelling: this procedure delivers the highest combined success rate in men with both PD and significant ED—curvature correction exceeding 85% and patient satisfaction rates consistently above 90% in long-term series, making it the most definitive single intervention for this patient profile. Overall, when patients are correctly selected and treated by fellowship-trained andrologists at high-volume centres—as coordinated by GAF Healthcare—the probability of achieving functional, intercourse-compatible penile straightening is 70–90% across the treatment spectrum.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides a fully managed, end-to-end medical tourism experience for Peyronie's Disease Treatment in both India and the UAE, encompassing every non-clinical touchpoint from pre-departure to post-treatment repatriation.
INDIA LOGISTICS:
• e-Medical Visa Assistance: GAF's India visa desk prepares and submits the complete e-Medical Visa application on the patient's behalf, including the mandatory hospital invitation letter from our partner JCI/NABH-accredited institution, ensuring approvals are typically secured within 3–5 business days. Extension applications are managed if the clinical stay is prolonged.
• Airport Transfers: Private air-conditioned vehicle transfers between the international airport and hospital/hotel are arranged for the patient and up to 2 accompanying attendants at all hours.
• Dedicated Bilingual Coordinator: A personal GAF case coordinator—fluent in English and the patient's native language—accompanies the patient to all clinical appointments, translates between the medical team and patient, and manages all administrative paperwork within the hospital.
• Attendant Accommodation: GAF arranges serviced apartments or hospital guest houses within walking distance of partner hospitals (available in Delhi, Mumbai, Chennai, Hyderabad, Bengaluru) at preferential rates, with meal, laundry, and SIM card support included in premium packages.
• Telemedicine Follow-Up: Post-departure, patients are enrolled in GAF's structured telemedicine programme—video consultations with the treating andrologist at Day 30, Day 90, and Month 6—ensuring continuity of the penile rehabilitation protocol and early identification of any complications.
UAE LOGISTICS:
• Visa Entry: Nationals of over 50 countries receive visa-on-arrival or visa-free access to the UAE for up to 30–90 days, covering the full treatment and recovery period for most international patients. GAF's UAE visa desk assists with prior-entry medical visa applications for nationalities requiring advance approval, coordinating with partner hospitals in Dubai Healthcare City (DHA-licensed) and Abu Dhabi (DoH-licensed).
• Airport Transfers: Luxury vehicle transfers (SUV or executive sedan) between Dubai International (DXB), Abu Dhabi International (AUH), or Al Maktoum International (DWC) and the patient's hospital or hotel are provided with meet-and-greet service.
• Hotel & Recovery Accommodation: GAF partners with medically adjacent hotels in Dubai Healthcare City and near Cleveland Clinic Abu Dhabi and Mediclinic City Hospital, offering in-room nursing check-in services for post-surgical recovery patients.
• Interpreter Services: On-call certified medical interpreters in Arabic, Russian, French, Urdu, and other languages are available for all consultations.
• Concierge & Lifestyle Support: For extended UAE stays, GAF's concierge team manages leisure recommendations, family activities, halal/dietary-specific meal arrangements, and prayer facility access—ensuring accompanying family members are comfortable throughout the medical journey.
ACROSS BOTH DESTINATIONS:
• Pre-Travel Medical File Review: All diagnostic records, imaging, and clinical notes are reviewed by a GAF-affiliated specialist prior to travel, providing a second-opinion report and a confirmed treatment plan so the patient arrives with a clear care pathway.
• Emergency Medical Liaison: 24/7 WhatsApp and phone access to GAF's medical case management team for any acute clinical concern during the in-country stay.
• Discharge Documentation: Comprehensive discharge pack including operative report, histopathology (if applicable), post-operative protocol, medication list, and fit-to-fly certificate provided in English and the patient's preferred language.